18 F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study

作者：Jiang Wu, Shao‐Hua Wang, Xianzhong Zhang, Zhaogang Teng, Jingjie Wang, Bryant C. Yung, Gang Niu, Hong Zhu, Guangming Lu, Xiaoyuan Chen · 发表于：Journal of Nuclear Medicine · 年份：2018 · DOI：10.2967/jnumed.118.208637 · 被引用次数：46 · 研究领域：Radiopharmaceutical Chemistry and Applications、Medical Imaging Techniques and Applications、Prostate Cancer Treatment and Research

18 F-alfatide II has been proven to have excellent clinical translational potential. In this study, we investigated 18 F-alfatide II for identifying breast cancer and compared the performances between 18 F-alfatide II and 18 F-FDG. Methods: Forty-four female patients with suspected primary breast cancer were recruited. PET/CT images using 18 F-alfatide II and 18 F-FDG were acquired within 7 d. Tracer uptake in breast lesions was evaluated by visual analysis, and semiquantitative analysis with SUV max and SUV mean . Results: Forty-two breast cancer lesions and 11 benign breast lesions were confirmed by histopathology in 44 patients. Both 18 F-alfatide II and 18 F-FDG had higher uptake in breast cancer lesions than in benign breast lesions ( P < 0.05 for 18 F-alfatide II, P < 0.05 for 18 F-FDG). The area under the curve of 18 F-alfatide II was slightly less than that of 18 F-FDG. Both 18 F-alfatide II and 18 F-FDG had high sensitivity (88.1% vs. 90.5%), high positive predictive value (88.1% vs. 88.4%), moderate specificity (54.5% vs. 54.5%), and moderate negative predictive value (54.5% vs. 60.0%) for differentiating breast cancer from benign breast lesions. By combining 18 F-alfatide II and 18 F-FDG, the sensitivity and negative predictive value significantly increased to 97.6% and 85.7%, respectively, with positive predictive value slightly increased to 89.1% and no change to the specificity (54.5%). The uptake of 18 F-alfatide II (SUV max : 3.77...